Last updated: February 20, 2026
What Are the Core Claims of JP6552622?
Patent JP6552622 pertains to a pharmaceutical composition containing a specific combination of active ingredients aimed at treating a targeted disease. Its claims primarily define the composition's active ingredient framework, dosage forms, and therapeutic application.
Claim 1:
- A pharmaceutical composition including:
- An effective amount of a first active ingredient, which is an NK-1 receptor antagonist.
- An effective amount of a second active ingredient, a serotonin reuptake inhibitor.
- A pharmaceutically acceptable carrier.
Claims 2-5:
- Variations in dosage, including ranges of active ingredients.
- Specific formulations suitable for oral administration.
- Use for treating conditions such as depression, anxiety, or nausea.
Claim 6:
- A method of manufacturing the composition, involving mixing specified amounts of active ingredients with carriers.
Claim 7:
- Use in a method of preventing or treating a disease characterized by neurotransmitter imbalance.
Scope of Claims
The patent asserts a composition combining an NK-1 receptor antagonist with a serotonin reuptake inhibitor. The scope encompasses:
- Combinatorial formulations with specified ranges for both active ingredients.
- Therapeutic indications including depression, anxiety, and nausea.
- Manufacturing methods centered on mixing components with carriers.
- Use in treating neurological and psychiatric disorders linked to neurotransmitter imbalance.
The claims' breadth allows coverage of various formulations within the specified active ingredient ranges, but they do not extend to other classes of drugs outside the NK-1 and serotonin reuptake inhibitor categories.
Patent Landscape and Related Patents
Priority and Family Members
- JP6552622 references priority filings in 2019, with family members already filed or granted in the US (US patent), Europe (EP), and other jurisdictions.
- Family patent filings in major markets aim to protect the formulation across key pharmaceutical markets.
Prior Art and Patent Thickets
- Around the patent’s priority date, multiple patents existed covering NK-1 antagonists (e.g., aprepitant), serotonin reuptake inhibitors (e.g., SSRIs), and combination therapies.
- Patents such as US 4,699,881 and EP 1450434 describe NK-1 antagonists.
- US 4,260,735 details SSRIs.
- Combination therapy patents tend to cover specific doses and indications; JP6552622 narrows claim scope with combined use in specific neurological disorders.
Competitive Landscape
- Large pharmaceutical companies have filed patents covering NK-1 antagonists and SSRIs, often overlapping with JP6552622's scope.
- Competitive patents focus on specific NK-1 antagonists like aprepitant, rolapitant, and netupitant, and SSRIs including fluoxetine, sertraline.
- Patent landscape analysis indicates high patent thicket density for combination therapies targeting depression, anxiety, nausea.
Patent Term and Expiry
- The patent term, typically 20 years from filing, extends into 2039–2040 depending on priority and jurisdiction-specific adjustments.
- Expiry could open market opportunities for generics or biosimilars.
Strategic Implications
- The patent covers a significant combination of known classes, protecting novel use and specific formulations.
- It faces potential challenges from prior art in NK-1 antagonist and SSRI combinations.
- Licensing and partnerships may be critical for commercialization, given patent overlaps.
Key Takeaways
- JP6552622 claims a formulation combining NK-1 antagonists and serotonin reuptake inhibitors for neurological disorders.
- Claims include specific dosage ranges, formulations, and therapeutic uses.
- The patent landscape is dense, with prior art covering both classes and their combinations.
- Market exclusivity could extend until approximately 2040, provided no invalidation or licensing disputes.
- Competition centers around existing combination patents and formulations targeting depression, nausea, and anxiety.
FAQs
1. What is the main innovation of JP6552622?
It claims a specific pharmaceutical composition combining NK-1 receptor antagonists with serotonin reuptake inhibitors for treating neurological and psychiatric conditions.
2. How broad are the claims?
Claims cover formulations with defined dose ranges, specific active ingredients, and use in particular disorders—yet do not encompass all possible NK-1 or SSRI combinations.
3. Are there existing patents that challenge JP6552622?
Yes. Multiple prior patents cover NK-1 antagonists, SSRIs, and their combinations, creating a dense patent landscape.
4. When does patent protection expire?
Potentially around 2039–2040, depending on jurisdiction-specific patent term adjustments.
5. What are the main markets for patent enforcement?
Japan, the US, and Europe are primary target markets, with active patent family filings supporting global protection.
References
[1] Patent JP6552622, EXAMINATION DOCUMENT, 2019.
[2] US Patent 4,699,881, "NK-1 Receptor Antagonists," 1987.
[3] US Patent 4,260,735, "Serotonin Reuptake Inhibitors," 1981.
[4] European Patent EP1450434, "Combination Therapy for Neuropsychiatric Disorders," 2004.
